State of Direct To Patient in Pharma
April 2025
Navigating Challenges and Opportunities in DTP Models
A DHC Group POV
About the POV
The pharmaceutical industry stands at a critical crossroads with Direct-to-Patient (DTP) models. Our latest POV reveals compelling data on this evolving landscape, drawing insights from industry leaders at EVERSANA, GoodRx, Wheel, and other pharmaceutical executives.
Our research uncovers a significant disconnect between how pharma perceives its patient-centricity and how patients actually experience it. This gap represents both a challenge and an opportunity for forward-thinking companies.
With patients increasingly making economically-driven healthcare decisions and HCPs adapting their practices accordingly, the traditional approaches to patient engagement are being fundamentally reshaped.
This comprehensive POV explores the various definitions of DTP across the industry, examines implementation frameworks that deliver measurable ROI, and provides actionable recommendations for pharmaceutical companies looking to enhance their patient engagement strategies.
Insights from Industry Leaders:
